Education
About Us
Working with TipRanks
Follow Us
Cyfuse Biomedical K.K. (JP:4892)
:4892
Total Valuation
Cyfuse Biomedical K.K. has a market cap or net worth of ¥6.64B. The enterprise value is ¥3.11B.
Market Cap¥6.64B
Enterprise Value¥3.11B
Share Statistics
Cyfuse Biomedical K.K. has 9,963,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,963,900
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Cyfuse Biomedical K.K.’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -20.35%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.18
Return on Invested Capital (ROIC)-20.35%
Return on Capital Employed (ROCE)-0.24
Revenue Per Employee11.00M
Profits Per Employee-36.37M
Employee Count21
Asset Turnover0.05
Inventory Turnover1.72
Valuation Ratios
The current PE Ratio of Cyfuse Biomedical K.K. is ―. Cyfuse Biomedical K.K.’s PEG ratio is 0.34.
PE Ratio―
PS Ratio22.48
PB Ratio1.88
Price to Fair Value1.88
Price to FCF-8.92
Price to Operating Cash Flow0.00
PEG Ratio0.34
Income Statement
In the last 12 months, Cyfuse Biomedical K.K. had revenue of 231.00M and earned -763.84M in profits. Earnings per share was -86.78.
Revenue231.00M
Gross Profit78.40M
Operating Income-828.18M
Pretax Income-761.30M
Net Income-763.84M
EBITDA-792.68M
Earnings Per Share (EPS)-86.78
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Cyfuse Biomedical K.K. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.70
52-Week Price Change-37.08%
50-Day Moving Average624.78
200-Day Moving Average681.48
Relative Strength Index (RSI)50.95
Average Volume (3m)50.89K
Important Dates
Cyfuse Biomedical K.K. upcoming earnings date is May 20, 2026, TBA (Confirmed).
Last Earnings DateFeb 13, 2026
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Cyfuse Biomedical K.K. as a current ratio of 4.54, with Debt / Equity ratio of 47.58%
Current Ratio4.54
Quick Ratio4.44
Debt to Market Cap0.25
Net Debt to EBITDA3.05
Interest Coverage Ratio-58.00
Taxes
In the past 12 months, Cyfuse Biomedical K.K. has paid 2.54M in taxes.
Income Tax2.54M
Effective Tax Rate>-0.01
Enterprise Valuation
Cyfuse Biomedical K.K. EV to EBITDA ratio is -3.51, with an EV/FCF ratio of -4.77.
EV to Sales12.03
EV to EBITDA-3.51
EV to Free Cash Flow-4.77
EV to Operating Cash Flow-5.20
Balance Sheet
Cyfuse Biomedical K.K. has ¥2.70B in cash and marketable securities with ¥766.00M in debt, giving a net cash position of ¥1.93B billion.
Cash & Marketable Securities¥2.70B
Total Debt¥766.00M
Net Cash¥1.93B
Net Cash Per Share¥193.97
Tangible Book Value Per Share¥313.30
Margins
Gross margin is 37.29%, with operating margin of -358.52%, and net profit margin of -330.67%.
Gross Margin37.29%
Operating Margin-358.52%
Pretax Margin-329.57%
Net Profit Margin-330.67%
EBITDA Margin-343.16%
EBIT Margin-358.52%
Analyst Forecast
The average price target for Cyfuse Biomedical K.K. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast56.17%
EPS Growth Forecast-11.63%